Calcitonin: hormone into oblivion


Authors: Broulík Petr
Authors‘ workplace: III. interní klinika 1. LF UK a VFN v Praze
Published in: Clinical Osteology 2019; 24(2): 53-56
Category:

Overview

Calcitonin is 32-aminoacids polypeptide whose primary function is to inhibit osteoclasts activated bone resorption. In mammals is secreted in the thyroid gland specialized cells called C cells which have embrygenic origin in ultimobranchial bodies. C cells are about 0.1 % of the mass of thyroid gland. To achieve hypocalcemic effect is necessary all 32 aminoacids. Calcitonin is released from thyroid gland first of all by calcium and magnesium. Calcitonin is decreasing bone resorption which can demonstrated in vivo and in vitro. Calcitonin has been used to treat osteoporosis and algodystrophic syndrome. It had a lot of studies with good results on bone mineral density and fracture rate. The benefit-risk balance in the post-menopausal osteoporosis indication that the CHMP considered negative and recommended the withdrawal from the market of all products authorized only in this single indication across the European Union. Intracranialy calcitonin act as a neurotransmiter. Prevailing opinion is view that calcitonin protects the skeleton under conditions of increased calcium demand as happens in times of growth, pregnancy and lactation. Calcitonin is also important tumor marker of thyroid carcinoma.

Keywords:

osteoporosis – C-cells – calcitonin – calcium – magnesium – thyroid gland


Sources
  1. Kumar MA. Foster GV, Macintyre I. Further evidence for calcitonin a rapid acting hormone which lowers plasma calcium. Lancet 1963; 2(7306): 480–482. Dostupné z DOI: <http://dx.doi.org/10.1016/s0140–6736(63)90224–1>.
  2. Struthers AD, Brown MJ, MacDonald DW et al. Human calcitonin gene related peptide: a potent endogenous vasodilator in man. Clin Sci (Lond) 1986; 70(4): 389–393.
  3. Blahoš J. Kalcitonin a fosfokalciový metabolismus. Jeho fyziologický a klinický význam. Avicenum: Praha 1974.
  4. Austin LA, Heath H. Physiology and pathophysiology of calcitonin. N Engl J Med 198l; 304(5): 269–278. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM198101293040505>.
  5. Blahoš J, Zamrazil V (eds). Endokrinologie: Interdisciplinární obor. Triton: Praha 2006:112–114. ISBN 80–7254–788–7.
  6. Broulik P. Kalcitonin a jeho úloha v regulaci kalciofosfátového metabolismu. Ćas Lek Česk 2010; 149(6): 285–287.
  7. Moonga BS, Alam AS, Bevis PJ et al. Regulation of cytosolic free calcium in isolated osteoclasts by calcitonin. J Endocrinol 1992; 132(2): 241–249. Dostupné z DOI: <http://dx.doi.org/10.1677/joe.0.1320241>.
  8. Del Fattore A, Teti A,Rucci N. Osteoclast receptors and signaling. Arch Biochem Biophys 2008; 473(2): 147–160. Dostupné z DOI: <http://dx.doi.org/10.1016/j.abb.2008.01.011>.
  9. Chambers TJ, Hall TJ. Cellular and molecular mechanisms in the regulation and function of osteoclasts. Vitam Horm 1991; 46: 41–86.
  10. Blahoš J, Care AD, Sommerville A. The effect of betamethazone on duodenal calcium absorption and 1,25-dihydroxyvitamine D production in the chick. Horm Metab Res 1983; 15(4): 197–200. Dostupné z DOI: <http://dx.doi.org/10.1055/s-2007–1018668>.
  11. Buclin T, Randin, JP, Jacquet AF et al. The effect of rectal and nasal administration of salomon calcitonin in normal subjects. Calcif Tissue Int 1987; 41(5): 252–258. Dostupné z DOI: <http://dx.doi.org/10.1007/bf02555225>.
  12. Wimalawansa SJ. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit Rev Neurobiol 1997; 11(2–3): 167–239.
  13. Yoshimura M. Analgesic mechanism of calcitonin. J Bone Miner Metab 2000; 18(4): 230–233.
  14. Chesnut CH, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000; 109(4): 267–276.
  15. Chesnut CH, Majumdar S, Newitt DC et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging:results from the QUEST study. J Bone Miner Res 2005; 20(9): 1548–1561. Dostupné z DOI: <http://dx.doi.org/10.1359/JBMR.050411>.
  16. Muller B, Becker KL, Schachinger H et al. Calcitonin precursors are reliable markers of sepsis in medical intensive care units. Crit Care Med 2000; 28(4): 977–983. Dostupné z DOI: <http://dx.doi.org/10.1097/00003246–200004000–00011>.
  17. Sato K, Hirata Y, Imai T et al. Characterization of immunoreactive adrenomedullin in human plasma and urine. Life Science 1995; 57(2): 189–194. Dostupné z DOI: <http://dx.doi.org/10.1016/0024–3205(95)00259–9>.
  18. Davey RA, Findlay DM. Calcitonin: Physiology or fantasy? J Bone Miner Res. 2013; 28(5): 973–979. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.1869>.
  19. Blahoš J. Osteoporóza. Galén: Praha 1995. ISBN 8085824264.
  20. Kovacs CS. Calcium and bone metabolism during pregnancy and lactation. J Mammary Gland Biol Neoplasia 2005; 10(2): 105–118. Dostupné z DOI: <http://dx.doi.org/10.1007/s10911–005–5394–0>.
  21. Sexton PM, Findlay DM, Martin TJ. Calcitonin. Curr Med Chem 1999; 6(11): 1067–1093.
  22. Findlay DM, Sexton PM. Calcitonin. Growth Factors 2004;22(4):217–224. Dostupné z DOI: <http://dx.doi.org/10.1080/08977190410001728033>.
  23. Papi G, Corsello SM, Cioni K et al. Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study. J Endocrinol Invest 2006; 29(5): 427–437. Dostupné z DOI: <http://dx.doi.org/10.1007/BF03344126>.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account